The lower the 'effortive lung capacity' level, the lower the survival rate of non-small cell lung cancer
Oct 23, 2024
|
Non-small cell lung cancer is the most common type of lung cancer, and immuno-cancer drugs are used as the main treatment method. However, it was difficult to accurately predict the treatment effect because the treatment response was different for each patient. For more accurate prediction of therapeutic effect, additional predictors were needed in addition to previously known ones such as gene, molecular analysis, and tumor size.
Previously, the focus was only on the anticancer effect of immuno-cancer drugs, but the study emphasized that lung function is closely related to various systemic conditions of patients and revealed that patients' lung function, especially effortless lung capacity (FVC), is an important predictor before treatment with immuno-cancer drugs.
Effortful lung capacity (FVC) is the amount of air the patient can breathe in as deeply as possible and then exhale as much as possible. This is not just an indicator of respiratory health, but is also closely related to general health status
A research team led by Professor Lim Jung-wook of respiratory internalization at the Catholic University of Korea Yeouido St. Mary's Hospital analyzed treatment results and survival rates after measuring FVC levels through lung function tests before receiving immuno-oncology treatment for 289 non-small cell lung cancer patients.
Patients with FVC below 70% of the predicted had poor results in immuno-oncology treatment, and their survival rates fell significantly. On the other hand, patients with normal FVC had relatively good treatment outcomes and longer survival periods.
In the intermediate survival period, the group with more than 70% of FVC showed a significant difference of 14.4 months and the control group was 6.1 months. In addition, the predictive power of FVC survival was valid in multivariate analysis with other variables.
Professor Lim Jung-wook (corresponding author) "Recent studies predicting the course of immuno-oncology treatment mainly focus on genetic analysis and molecular analysis, but these techniques are difficult to apply to all patients."This study has found that making good use of basic test results such as lung function is also very helpful in patient treatment," he said.
Since lung capacity is not simply a representation of respiratory health, but is closely related to various systemic conditions, managing respiratory conditions is essential when treating lung cancer. "In addition, respiratory rehabilitation or lung function enhancement programs can help patients with decreased lung function."
This study is a joint study of seven hospitals belonging to the Catholic Central Medical Center and was recently published in the international journal Therapeutics Advances in Medical Oncology (IF=4.3).
|
bellho@sportschosun.com
